Stakeholder Views on SCOTUS Purge of 6-Month Marketing Pause for Biosimilars

Pharmaceutical manufacturers, pharmacy benefit managers, and various trade groups respond to the recent Supreme Court decision on the 6-month marketing rule post FDA approval for biosimilars.
Jackie Syrop
June 20, 2017
In a much-anticipated decision, the US Supreme Court ruled unanimously in the Sandoz v Amgen case that biosimilar makers do not have to wait an additional 180 days after FDA approval of their biosimilar product before they launch it. The ruling gives biosimilar makers the flexibility to provide notice of commercial marketing to the reference drug developer either before or after the FDA’s approval of their biosimilar product.
 
Sandoz developed a biosimilar for Amgen’s filgrastim (Neupogen), marketed as filgrastrim-sndz (Zarxio), which was the first biosimilar approved in the United States in 2015.
 
The court stated that there is no existing rule in the 2010 Biologics Price Competition and Innovation Act (BPCIA) that would force biosimilar makers to comply with the so-called “patent dance”—an information-exchange process in which a biosimilar maker provides manufacturing/patent information along with the Biologics License Application (BLA) to the reference drug maker—but said the issue should be decided by states.
 
The court’s ruling, written by Justice Clarence Thomas, was a response to one of the major questions the Justices considered at the April 2017 hearing on the case, during which Amgen sought to convince the court that Sandoz and other biosimilar makers would have to wait 6 additional months after FDA approval to market biosimilars. Sandoz argued that such a decision would effectively create an additional 6 months of market exclusivity.
 
Some analysts view the court’s decision as very narrow and they do not trust it to resolve all the issues in the case. In their opinion, this might set the stage for the FDA to be more involved in the patent dance and in further interpretation of the BPCIA. In a concurring opinion, Justice Steven Breyer wrote that Congress delegated to the FDA authority to interpret the terms of the BPCIA, and if the agency decides a different interpretation would better serve the objectives of the BPCIA, it may well have the authority to modify the court’s interpretation.  
 
Carol Lynch, global head of biopharmaceuticals at Sandoz, said the Justices’ unanimous ruling on the notice of commercial marketing will help expedite patient access to life-enhancing treatments, and that the clarity provided on the patent dance will help the biosimilars industry move forward. Amgen’s spokesperson said the company was disappointed in the decision, and would continue to seek to enforce the company’s intellectual property against those parties that infringe upon their rights.
 
The SCOTUS decision was hailed by other biosimilar makers, which expect the decision to speed marketing of their biosimilars. Biocon’s corporate medical director Kiran Mazumdar-Shaw said, “We are pleased with the US Supreme Court decision as it clarifies that the BPCIA was intended to facilitate the entry of biosimilar drugs into the market and not grant an additional 6 months of exclusivity to innovators.” Biocon has 2 potential biosimilars currently under FDA review (pegfilgrastim and trastuzumab) and is in the process of filing a BLA for insulin glargine. “By reducing the uncertainty around the introduction of biosimilars in the US, this development augurs well for the continued expansion of the US biosimilars market,” she said.
 


x-button

Health economics experts. Managed care professionals. Key clinical specialists. This is where the worlds of clinical, regulatory, and economical outcomes for specialized pharmaceutical biotechnology meet: The Center for Biosimilars is your online resource for emerging technologies, with a focus on improving critical thinking in the field to impact patient outcomes. We’ll discuss the current landscape for advanced health care management—reviewing emerging treatment paradigms, approaches, and considerations—all by authoritative industry voices.

Intellisphere, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747
Copyright © 2006-2019 Intellisphere, LLC. All Rights Reserved.